AI
AIFF.US Firefly Neuroscience, Inc.
- Market cap
- USD 14.7M
- P/E
- -
- P/B
- 1.13x
- ROE
- -54.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AIFF.US undervalued?
Graham numberThe Graham number of Firefly Neuroscience, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Firefly Neuroscience, Inc. fundamental analysis
No fundamental analysis for Firefly Neuroscience, Inc. yet.
Firefly Neuroscience, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Firefly Neuroscience, Inc.
Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as s…
Full company profileFirefly Neuroscience, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Firefly Neuroscience, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 13.9M | 32.0K | 0.00 | 498K | 108K | 1.14M | 2.19M |
| Gross Profit | 2.21M | 32.0K | 0.00 | 498K | 41.0K | 645K | 1.33M |
| Operating Income | 412K | -4.65M | -3.33M | -3.08M | -9.18M | -8.61M | -7.37M |
| EBITDA | 425K | -3.82M | -3.20M | -2.58M | -10.3M | -19.5M | -7.14M |
| Net Income | 413K | -4.38M | -3.79M | -2.60M | -10.5M | -19.9M | -7.29M |
| EPS | 0.05 | -0.56 | -0.48 | -0.33 | -1.60 | -1.47 | -0.34 |
| Balance Sheet | |||||||
| Total Assets | 3.77M | 953K | 135K | 2.64M | 4.60M | 10.5M | 15.4M |
| Total Liabilities | 2.16M | 3.97M | 2.25M | 2.53M | 4.98M | 2.84M | 2.02M |
| Shareholders' Equity | 1.61M | -3.01M | -2.11M | 109K | -375K | 7.64M | 13.4M |
| Cash & Short-term Investments | 1.86M | 653K | 58.0K | 2.14M | 1.81M | 2.75M | 8.02M |
| Total Debt | 496K | 1.79M | - | - | 694K | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | 423K | -3.82M | -2.89M | -2.17M | -6.16M | -8.19M | -6.44M |
| Capital Expenditure | 64.5K | 0.00 | 0.00 | 386K | 415K | 128K | 267K |
| Free Cash Flow | 359K | -3.82M | -2.89M | -2.56M | -6.57M | -8.32M | -6.44M |
| Ratios | |||||||
| ROE | 25.6% | - | - | -2,388.1% | - | -260.3% | -54.3% |
| ROA | 11.0% | -459.7% | -2,806.7% | -98.6% | -227.3% | -189.8% | -47.2% |
| Net Profit Margin | 3.0% | -13,690.6% | - | -522.7% | -9,685.2% | -1,741.0% | -332.1% |
| Debt to Equity | 0.31x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Firefly Neuroscience, Inc. dividends
Firefly Neuroscience, Inc. has not paid dividends in the last 6 fiscal years.
Last stock split: 1:3 on Aug 13, 2024.
Who owns Firefly Neuroscience, Inc.
- Insiders 9.34%
- Institutions 10.86%
- Public & others 79.81%
- Shares outstanding 15.7M
- Free float 13.5M
Top funds holding AIFF.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 59.9K | 0.38% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 43.2K | 0.28% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 19.6K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 15.4K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 3.30K | 0.02% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 2.85K | 0.02% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.77K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding AIFF.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Murchinson Ltd. | 650K | 4.14% | 0.00% | Jun 2026 |
| BlackRock Inc | 187K | 1.19% | +10.51% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 179K | 1.14% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 122K | 0.77% | -22.25% | Jun 2026 |
| Vanguard Capital Management, LLC | 112K | 0.71% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 67.8K | 0.43% | -62.36% | Jun 2026 |
| UBS Group AG | 59.1K | 0.38% | -55.28% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 51.0K | 0.33% | 0.00% | Jun 2026 |
| State Street Corp | 46.3K | 0.30% | 0.00% | Jun 2026 |
| Cygnus Capital Advisors, LLC | 44.6K | 0.28% | +122.33% | Jun 2026 |
| Northern Trust Corp | 33.5K | 0.21% | +112.47% | Jun 2026 |
| Virtu Financial LLC | 26.6K | 0.17% | 0.00% | Jun 2026 |
| Squarepoint Ops LLC | 14.3K | 0.09% | 0.00% | Jun 2026 |
| Waldron, LP | 12.0K | 0.08% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 5.93K | 0.04% | +116.91% | Jun 2026 |
| Vanguard Global Advisers, LLC | 2.77K | 0.02% | 0.00% | Jun 2026 |
| Citigroup Inc | 2.09K | 0.01% | -92.70% | Jun 2026 |
| Advisor Group Holdings, Inc. | 1.46K | 0.01% | 0.00% | Jun 2026 |
| Barclays PLC | 312.00 | 0.00% | 0.00% | Jun 2026 |
| Tradewinds Capital Management, LLC | 40.00 | 0.00% | 0.00% | Jun 2026 |
Firefly Neuroscience, Inc. company profile
- Company name
- Firefly Neuroscience, Inc.
- Ticker
- AIFF.US
- Exchange
- USA Stocks
- Listed since
- Feb 23, 2011
- Sector
- Technology
- Industry
- IT Services
- Employees
- 17
- Fiscal year end
- December
- Address
- 1100 Military Road, Kenmore, NY, United States, 14217
- Phone
- 888 237 6412
- Website
- fireflyneuro.com
About Firefly Neuroscience, Inc.
Firefly Neuroscience, Inc., an artificial intelligence company, develops, markets, and distributes medical devices and technologies that allow high-resolution visualization and evaluation of the complex neurophysiological interconnections of the human brain in North America. The company offers the Evoke System, a system used to perform electroencephalographic (EEG) and event-related potential (ERP) assessments, which are analyzed by its cloud-based platform and returned as structured reports designed to support clinical decision-making for various diseases, including depression, anxiety, ADHD, PTSD, MCI, dementia, Parkinson's disease, bipolar disorder, schizophrenia, schizoaffective disorder, ASD, and traumatic brain injury. It serves clinicians. Firefly Neuroscience, Inc. was founded in 2006 and is based in Kenmore, New York.
Firefly Neuroscience, Inc. management
5- Mr. Greg LipschitzCEO & Director · born 1989
- Mr. David DeCaprioPresident, COO & Director · born 1973
- Mr. Gil IssacharHead of AI & Neuroscience · born 1983
- Mr. Paul Krzywicki CPA, CGACompany Secretary · born 1985
- Ms. Jessica L. PazChief Accounting Officer · born 1980